MMDA-2

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
MMDA-2
Clinical data
Other names2-Methoxy-4,5-methylenedioxyamphetamine; 6-Methoxy-3,4-methylenedioxyamphetamine; 6-Methoxy-MDA; 6-MeO-MDA
Routes of
administration		Oral
ATC code
  • None
Legal status
Legal status
Identifiers
  • 1-(6-methoxy-1,3-benzodioxol-5-yl)propan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
E number{{#property:P628}}
CompTox Dashboard (EPA)
  • {{#property:P3117}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 29: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC11H15NO3
Molar mass209.245 g·mol−1
3D model (JSmol)
  • O1c2cc(c(OC)cc2OC1)CC(N)C

MMDA-2, also known as 2-methoxy-4,5-methylenedioxyamphetamine or as 6-methoxy-MDA, is a psychedelic drug of the phenethylamine, amphetamine, and MDxx families.[1] It is closely related to MMDA and MDA.[1]

Alexander Shulgin was likely the first to synthesize MMDA-2.[1] In his book PiHKAL (Phenethylamines I Have Known and Loved), the dose is listed as 25 to 50 mg, and the duration is listed as 8 to 12 hours.[1] Shulgin reports that MMDA-2 produces effects such as enhanced awareness, empathy, and visual facilitation and distortion, as well as some side effects like gastrointestinal upset and appetite loss.[1] He states that 30 mg is very similar to 80 mg of MDA, and also remarks that it would be impossible for anyone to have a bad experience on the drug at that dose.[1]

It has been found that MMDA-2, unlike MMDA but similarly to 6-methyl-MDA, is very weak or negligible at inducing the release of serotonin or dopamine,[2] and accordingly, does not produce amphetamine-like responses in animals in drug discrimination studies.[3] Instead, MMDA-2 is likely to act as a pure serotonin 5-HT2 receptor agonist similarly to the DOx series of compounds, with activation of the serotonin 5-HT2A receptor conferring its psychedelic effects.[4]

MMDA-2 has been sold as a designer drug in Japan.[5]

See also

[edit | edit source]

References

[edit | edit source]
  1. ^ a b c d e f Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  2. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  3. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  4. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
  5. ^ Lua error in Module:Citation/CS1/Configuration at line 2172: attempt to index field '?' (a nil value).
[edit | edit source]
Retrieved from "http://70.231.62.181/index.php?title=MMDA-2&oldid=11247039"